Skip Navigation


JAC Advance Access originally published online on August 13, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/3/345    most recent
dkg348v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walsh, F.
Right arrow Articles by Amyes, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, F.
Right arrow Articles by Amyes, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2003) 52, 345-353
© 2003 The British Society for Antimicrobial Chemotherapy

High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae

Fiona Walsh1,*, Joanne Willcock2 and Sebastian Amyes1

1 Department of Medical Microbiology, Medical School, University of Edinburgh, Edinburgh EH8 9AG; 2 Aventis Pharma Ltd., Kings Hill, West Malling, Kent ME19 4 AH, UK

Received 29 November 2002; returned 22 January 2003; revised 8 May 2003; accepted 29 May 2003

Resistance to macrolides in Streptococcus pneumoniae is usually mediated by methylation of 23S ribosomal RNA, encoded by the erm(B) methylation gene, or by efflux mediated by the mef(A) gene. Changes in the L4 and L22 ribosomal proteins have also been associated with macrolide resistance and reduced telithromycin activity. This study generated in vitro mutants from three parent strains of S. pneumoniae: 02J1175 [mef(A) +], 02J1095 [erm(B) +] and NCTC 13593 (macrolide susceptible). The erm(B) and the erm(B) upstream region, the mef(A) genes and the mef(A) upstream and downstream regions, the 23S rRNA genes encoding domains II and V and the L4 and L22 genes of the telithromycin-resistant strains were all amplified by PCR and all, except the mef(A) upstream and downstream regions, were sequenced. No changes were present in any of the genes of the mef(A) + mutants. No changes were found in the erm(B) genes, the 23S rRNA genes or the L4 protein genes of the erm(B) + mutants. However, a Lys-94 to Gln-94 amino acid mutation did occur in a mutant derived from erm(B) + with a telithromycin MIC of >32 mg/L. A 210 base pair deletion in the erm(B) upstream region was also present in this strain. We believe this is the first incidence of a Lys-94 to Gln-94 change in L22 associated with telithromycin resistance and also the first time that such a large deletion in the erm(B) upstream region has been identified in S. pneumoniae.

Keywords: telithromycin, Streptococcus pneumoniae, resistance

* Corresponding author. Tel: +44-131-6508270; Fax: +44-131-6511385; E-mail: fwalsh{at}staffmail.ed.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
N. Wolter, A. M. Smith, D. J. Farrell, J. B. Northwood, S. Douthwaite, and K. P. Klugman
Telithromycin Resistance in Streptococcus pneumoniae Is Conferred by a Deletion in the Leader Sequence of erm(B) That Increases rRNA Methylation
Antimicrob. Agents Chemother., February 1, 2008; 52(2): 435 - 440.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
R. Isozumi, Y. Ito, T. Ishida, M. Osawa, T. Hirai, I. Ito, K. Maniwa, M. Hayashi, H. Kagioka, M. Hirabayashi, et al.
Genotypes and Related Factors Reflecting Macrolide Resistance in Pneumococcal Pneumonia Infections in Japan
J. Clin. Microbiol., May 1, 2007; 45(5): 1440 - 1446.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
N. Wolter, A. M. Smith, D. E. Low, and K. P. Klugman
High-Level Telithromycin Resistance in a Clinical Isolate of Streptococcus pneumoniae
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1092 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
A. Al-Lahham, P. C. Appelbaum, M. van der Linden, and R. R. Reinert
Telithromycin-Nonsusceptible Clinical Isolates of Streptococcus pneumoniae from Europe
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3897 - 3900.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. Berisio, N. Corti, P. Pfister, A. Yonath, and E. C. Bottger
23S rRNA 2058A->G Alteration Mediates Ketolide Resistance in Combination with Deletion in L22
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3816 - 3823.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
D. Faccone, P. Andres, M. Galas, M. Tokumoto, A. Rosato, and A. Corso
Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones
J. Clin. Microbiol., November 1, 2005; 43(11): 5800 - 5803.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
E. Culebras, I. Rodriguez-Avial, C. Betriu, and J. J. Picazo
Differences in the DNA sequence of the translational attenuator of several constitutively expressed erm(A) genes from clinical isolates of Streptococcus agalactiae
J. Antimicrob. Chemother., November 1, 2005; 56(5): 836 - 840.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
T. Hisanaga, D. J. Hoban, and G. G. Zhanel
Mechanisms of resistance to telithromycin in Streptococcus pneumoniae
J. Antimicrob. Chemother., September 1, 2005; 56(3): 447 - 450.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
K. Kosowska, D. B. Hoellman, G. Lin, C. Clark, K. Credito, P. McGhee, B. Dewasse, B. Bozdogan, S. Shapiro, and P. C. Appelbaum
Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1932 - 1942.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
I. Rodriguez-Avial, C. Rodriguez-Avial, E. Culebras, and J. J. Picazo
In Vitro Activity of Telithromycin against Viridans Group Streptococci and Streptococcus bovis Isolated from Blood: Antimicrobial Susceptibility Patterns in Different Groups of Species
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 820 - 823.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
V. Matic, K. Kosowska, B. Bozdogan, L. M. Kelly, K. Smith, L. M. Ednie, G. Lin, K. L. Credito, C. L. Clark, P. McGhee, et al.
Antipneumococcal Activities of Two Novel Macrolides, GW 773546 and GW 708408, Compared with Those of Erythromycin, Azithromycin, Clarithromycin, Clindamycin, and Telithromycin
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4103 - 4112.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. Powis, A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, et al.
In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002
Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3305 - 3311.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.